These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 32992341)

  • 21. Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.
    Ramchandren R; Advani RH; Ansell SM; Bartlett NL; Chen R; Connors JM; Feldman T; Forero-Torres A; Friedberg JW; Gopal AK; Gordon LI; Kuruvilla J; Savage KJ; Younes A; Engley G; Manley TJ; Fenton K; Straus DJ
    Clin Cancer Res; 2019 Mar; 25(6):1718-1726. PubMed ID: 30617130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
    Evens AM; Connors JM; Younes A; Ansell SM; Kim WS; Radford J; Feldman T; Tuscano J; Savage KJ; Oki Y; Grigg A; Pocock C; Dlugosz-Danecka M; Fenton K; Forero-Torres A; Liu R; Jolin H; Gautam A; Gallamini A
    Haematologica; 2022 May; 107(5):1086-1094. PubMed ID: 34162178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.
    Bartlett NL
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):317-323. PubMed ID: 29222273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
    Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimated impact of ECHELON-1 overall survival on productivity costs in stage III/IV classical Hodgkin lymphoma in the United States.
    Phillips T; Liu N; Bloudek B; Migliaccio-Walle K; Reynolds J; Burke JM
    J Manag Care Spec Pharm; 2023 Dec; 29(12):1312-1320. PubMed ID: 37921077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma.
    Böll B; Bredenfeld H; Görgen H; Halbsguth T; Eich HT; Soekler M; Markova J; Keller U; Graeven U; Kremers S; Geissler M; Trenn G; Fuchs M; von Tresckow B; Eichenauer DA; Borchmann P; Engert A
    Blood; 2011 Dec; 118(24):6292-8. PubMed ID: 21917759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.
    Rubinstein PG; Moore PC; Bimali M; Lee JY; Rudek MA; Chadburn A; Ratner L; Henry DH; Cesarman E; DeMarco CE; Costagliola D; Taoufik Y; Ramos JC; Sharon E; Reid EG; Ambinder RF; Mitsuyasu R; Mounier N; Besson C; Noy A; ;
    Lancet Haematol; 2023 Aug; 10(8):e624-e632. PubMed ID: 37532416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
    Connors JM; Jurczak W; Straus DJ; Ansell SM; Kim WS; Gallamini A; Younes A; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Oki Y; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Chen R; Ramchandren R; Zinzani PL; Cunningham D; Rosta A; Josephson NC; Song E; Sachs J; Liu R; Jolin HA; Huebner D; Radford J;
    N Engl J Med; 2018 Jan; 378(4):331-344. PubMed ID: 29224502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tislelizumab monotherapy in patients with previously untreated early-stage classical Hodgkin lymphoma: a real-world study.
    Sun P; Yang H; Wang Y; Zhao B; Nie M; Huang K; Li Z
    Ann Hematol; 2024 Mar; 103(3):793-801. PubMed ID: 37953379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
    Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
    Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
    Russo F; Corazzelli G; Frigeri F; Capobianco G; Aloj L; Volzone F; De Chiara A; Bonelli A; Gatani T; Marcacci G; Donnarumma D; Becchimanzi C; de Lutio E; Ionna F; De Filippi R; Lastoria S; Pinto A
    Br J Haematol; 2014 Jul; 166(1):118-29. PubMed ID: 24673727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.
    Carella AM; Corradini P; Mussetti A; Ricardi U; Vitolo U; Viviani S
    Ann Hematol; 2018 Aug; 97(8):1301-1315. PubMed ID: 29802458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).
    Ogura M; Itoh K; Kinoshita T; Fukuda H; Takenaka T; Ohtsu T; Kagami Y; Tobinai K; Okamoto M; Asaoku H; Sasaki T; Mikuni C; Hirano M; Chou T; Ohnishi K; Ohno H; Nasu K; Okabe K; Ikeda S; Nakamura S; Hotta T; Shimoyama M
    Int J Hematol; 2010 Dec; 92(5):713-24. PubMed ID: 21076995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy.
    Zubizarreta PA; Alfaro E; Guitter M; Sanchez La Rosa C; Galluzzo ML; Millán N; Fiandrino F; Felice MS
    J Pediatr Hematol Oncol; 2017 Nov; 39(8):602-608. PubMed ID: 28902084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.
    Arakelyan N; Jais JP; Delwail V; Brière J; Moles-Moreau MP; Sénécal D; Berthou C; Desablens B; Colonna P; Andrieu JM;
    Cancer; 2010 Sep; 116(17):4054-62. PubMed ID: 20564152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.
    Anderson RA; Remedios R; Kirkwood AA; Patrick P; Stevens L; Clifton-Hadley L; Roberts T; Hatton C; Kalakonda N; Milligan DW; McKay P; Rowntree C; Scott FM; Johnson PWM
    Lancet Oncol; 2018 Oct; 19(10):1328-1337. PubMed ID: 30220622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma.
    Vassilakopoulos TP; Liaskas A; Pereyra P; Panayiotidis P; Angelopoulou MK; Gallamini A
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ABVD plus rituximab
    Strati P; Fanale MA; Oki Y; Turturro F; Fayad LE; Bartlett NL; Gladstone DE; Kasamon YL; Portlock CS; Wilson WH; Goy A; Younes A; Lee HJ
    Haematologica; 2019 Feb; 104(2):e65-e67. PubMed ID: 30190343
    [No Abstract]   [Full Text] [Related]  

  • 40. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma.
    Park SI; Shea TC; Olajide O; Reddy NM; Budde LE; Ghosh N; Deal AM; Noe JF; Ansell SM
    Blood Adv; 2020 Jun; 4(11):2548-2555. PubMed ID: 32516414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.